publication date: Mar. 13, 2015

Cancer Centers Join to Accelerate Trials, Industry Collaborations, Drug Development

Six NCI-designated cancer centers have agreed to pool data from their electronic medical record systems and cancer registries to accelerate discovery of targets and the development of biomarkers.

Launched in May 2014, the Oncology Research Information Exchange Network, or ORIEN, was founded by Moffitt Cancer Center and The Ohio State Comprehensive Cancer Center (The Cancer Letter, May 30, 2014).

Recently, ORIEN added four cancer centers: City of Hope, University of Virginia Cancer Center, University of Colorado Cancer Center, and the University of New Mexico Cancer Center (The Cancer Letter, Feb. 27).

The partnership is pursuing these fundamental goals:

• Obtain patient tissue data across multiple institutions to expedite clinical trial matching and provide support for clinical decisions,

• Create a federated database that member organizations are able to use for research,

• Charge pharmaceutical companies and other potential clients for access to the data, and

• Accelerate targeted discoveries and therapies for cancer patients.

The collaboration has so far accrued data from approximately 120,000 patients. The four new partners would add 50,000 patients each year.

ORIEN is built around a standard consenting and processing protocol called Total Cancer Care.

To join ORIEN, each new member pays $30,000 a year to train staff and implement Total Cancer Care—efforts that are overseen by M2Gen, the Moffitt biotechnology and informatics company that runs ORIEN.

“It is fairly unique to use one protocol amongst all centers,” said Bill Dalton, CEO of … Continue reading 41-10 Cancer Centers Join to Accelerate Trials, Industry Collaborations, Drug Development

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.